6I5I
Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound 12h
Summary for 6I5I
Entry DOI | 10.2210/pdb6i5i/pdb |
Descriptor | Dual specificity protein kinase CLK1, 5-(1-methylpyrazol-4-yl)-3-[1-(phenylmethyl)pyrazol-4-yl]furo[3,2-b]pyridine, 1,2-ETHANEDIOL, ... (4 entities in total) |
Functional Keywords | splicing kinase, furopyridine, inhibitor, clk, structural genomics, structural genomics consortium, sgc, transferase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 40681.72 |
Authors | Chaikuad, A.,Arrowsmith, C.H.,Edwards, A.M.,Bountra, C.,Paruch, K.,Knapp, S.,Structural Genomics Consortium (SGC) (deposition date: 2018-11-13, release date: 2019-01-09, Last modification date: 2024-01-24) |
Primary citation | Nemec, V.,Hylsova, M.,Maier, L.,Flegel, J.,Sievers, S.,Ziegler, S.,Schroder, M.,Berger, B.T.,Chaikuad, A.,Valcikova, B.,Uldrijan, S.,Drapela, S.,Soucek, K.,Waldmann, H.,Knapp, S.,Paruch, K. Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. Angew. Chem. Int. Ed. Engl., 58:1062-1066, 2019 Cited by PubMed: 30569600DOI: 10.1002/anie.201810312 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.6 Å) |
Structure validation
Download full validation report